Skip to main content
Clinical Trials/ISRCTN30371072
ISRCTN30371072CompletedNot Applicable

Effects of Mediterranean-style diet on inflammation markers and reversion of metabolic syndrome in cancer patients: role of plasmatic calprotectin

ational Cancer Institute G. Pascale Foundation0 sites150 target enrollmentStarted: October 19, 2015Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
150

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
All

Inclusion Criteria

  • 1. Aged between 18 and 65 years
  • 2. Oncology patients
  • 3. Have at least three of the following characteristics:
  • 3.1. Waist circumference of at least 88 cm in women and 102 cm in men
  • 3.2. Low levels of serum high density lipoprotein cholesterol (HDL), specifically less than 40 mg/dL for men and less than 50 mg/dL for women (or taking drug treatment for reduced HDL-C)
  • 3.3. Hypertriglyceridemia with triglycerides level of at least 150 mg/dL (or taking drug treatment for elevated triglycerides is an alternate indicator)
  • 3.4. Systolic blood pressure of at least 130 mmHg and diastolic blood pressure of at least 85 mmHg (or taking antihypertensive drug treatment in a patient with a history of hypertension)
  • 3.5. Fasting plasma glucose value of 100 mg/dL or greater due to loss of glucose homeostasis (or taking drug treatment of elevated glucose is an alternate indicator)

Exclusion Criteria

  • 1. Patients with cognitive and psychosocial problems
  • 2. Genetic disorders
  • 3. Smokers
  • 4. Drug addicts or abusers of alcohol (consumption of at least =500 g/wk in the last year)

Investigators

Sponsor
ational Cancer Institute G. Pascale Foundation

Similar Trials